Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Other Working Capital Changes (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Other Working Capital Changes for 6 consecutive years, with -$779709.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes fell 140.61% to -$779709.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.3 million, a 243.62% decrease, with the full-year FY2024 number at $251965.0, up 118.1% from a year prior.
  • Other Working Capital Changes was -$779709.0 for Q3 2025 at Ensysce Biosciences, down from $432474.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.9 million in Q3 2024 to a low of -$1.5 million in Q4 2024.
  • A 5-year average of -$103044.6 and a median of -$226810.0 in 2023 define the central range for Other Working Capital Changes.
  • Biggest YoY gain for Other Working Capital Changes was 1523.7% in 2022; the steepest drop was 1035.43% in 2022.
  • Ensysce Biosciences' Other Working Capital Changes stood at $932527.0 in 2021, then plummeted by 226.24% to -$1.2 million in 2022, then soared by 86.67% to -$156929.0 in 2023, then plummeted by 841.37% to -$1.5 million in 2024, then soared by 47.22% to -$779709.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Other Working Capital Changes are -$779709.0 (Q3 2025), $432474.0 (Q2 2025), and -$433659.0 (Q1 2025).